Novavax creates a more traditional shot than the other three Covid-19 A vaccine is available for use in the United States – and one is already available in Europe and many other countries.
Nearly a quarter of American adults still haven’t gotten their primary vaccine even late into the pandemic, and experts expect at least some of them to roll up their sleeves to a conventional option. than – protein-based vaccines.
The Maryland company also hopes its photos can become a top enhancement pick in the US and beyond. Tens of millions of Americans still need boosters that experts call vital for the best possible protection as the coronavirus continues to mutate.
Present, FDA authorized the initial two-dose series of Novavax for persons 18 years of age and older.
“I encourage anyone who is eligible, but has not been vaccinated against Covid-19 to consider doing so,” FDA Commissioner Dr. Robert Califf said in a statement.
Before the injections are started, the Centers for Disease Control and Prevention must recommend how they should be used, with a decision expected next week.
Novavax CEO Stanley Erck told the AP news agency he expects the United States to expand use of the vaccine beyond unvaccinated adults fairly quickly.
The FDA is currently evaluating it for people under the age of 12, Erck said. Novavax also submitted booster dose data, including “combination and combination” use in people who had previously received Pfizer or Moderna vaccines.
So far, the Biden administration has purchased 3.2 million doses of Novavax, and Erck said vaccinations will begin later this month.
Sharon Bentley of Argyle, Texas, is one of the holders. Bentley was hesitant about the first Covid-19 vaccines, but then her husband volunteered to test Novavax, giving it two doses and then a booster.
Her husband’s positive experience with a tried and true technology, “it convinced me,” Bentley said, adding that she also plans to tell some unvaccinated friends about it. this option.
The Novavax vaccine is made from copies of the spike protein that covers the coronavirus, packaged into nanoparticles for the immune system like a virus.
Then an immune-boosting ingredient, or adjuvant, made from South American bark is added to act as a red flag to ensure those seeds look suspicious enough to trigger an immune response. Powerful translation.
Protein vaccines have been used for many years to prevent hepatitis B, shingles, and other diseases.
It’s a very different technology from the dominant Pfizer and Moderna Covid-19 vaccines, which provide genetic instructions for the body to produce its own copies of the mutant protein. The less commonly used Johnson and Johnson selection uses a harmless cold virus to provide mutagenesis instructions.
Like other vaccines used in the US, Novavax shots have proven highly effective in preventing the most severe outcomes of Covid-19.
Typical vaccine reactions are mild, including arm pain and fatigue. But the FDA has warned of the possibility of a rare risk, heart inflammation, that has also occurred with the Pfizer and Moderna vaccines.
The Novavax vaccine was tested long before the omicron variant appeared. But last month, the company released data showing that a booster dose promises a strong immune response even to omicron’s newest relative – preliminary evidence that some of its scientific advisers have found. FDA called attractive.
However, US regulators are planning a fall boost campaign using Pfizer and Moderna photos that better target omicron subtypes – and Novavax has also begun testing updated photos. Erck said the company could have the updated dose available by the end of the year.
European regulators recently approved the use of the Novavax vaccine for children as young as 12 years old, and several countries have authorized the use of a booster dose of its parent vaccine.
Previous vaccine production difficulties have made the vaccine difficult, although Erck said those problems have been resolved and Novavax can meet global demand.
The majority of the company’s vaccines, including doses for the US, are being produced by the Serum Institute of India, the world’s largest vaccine producer.